BOGOTA, Colombia, April 12, 2013 \/PRNewswire\/ -- Startup biotechnology company Neuralgene (http:\/\/neuralgene.com<\/a>) has announced that it will begin animal studies in May to evaluate the efficacy of PRCN-829, its new gene therapy agent for the treatment of amyotrophic lateral sclerosis (ALS). PRCN-829 is the first gene therapy for sporadic ALS. <\/p>\n (Photo: http:\/\/photos.prnewswire.com\/prnh\/20130412\/PH93428-a<\/a> ) <\/p>\n (Photo: http:\/\/photos.prnewswire.com\/prnh\/20130412\/PH93428-b<\/a> ) <\/p>\n Neuralgene's neurotropic AAV-based gene therapy platform for the treatment of neurodegenerative diseases is based on the stem cell work performed by Jason Williams, M.D., founder and CEO of Neuralgene. \"This technology addresses several key aspects of the underlying pathology of ALS,\" said Leonardo Gonzalez, M.D., clinical researcher for Neuralgene. \"In his stem cell work, Dr. Williams had identified that production of Factor H by fat-derived mesenchymal stem cells may be a key mode of action.\" <\/p>\n The gene therapy is based on Dr. Williams' discovery that certain proteins produced by stem cells inhibit the attack of ALS. During the development of the gene therapy, he added new targets: neural growth factors and a protein implicated in ALS named TDP-43. \"When Dr. Williams demonstrated the concept behind stem cells and how to address the treatment of ALS using gene therapy, we immediately knew that this was a revolutionary new concept,\" said Dr. Gonzalez. <\/p>\n The PRCN-829 gene therapy is designed to not only target gene delivery to the brain and spinal cord, but also to genetically engineer stem cells. The AAV9 viral vector delivers multiple genes, which include Factor H (a regulator of complement activity), neural growth factors and regulators of TDP-43, to the neural cells. Initial animal studies have demonstrated the safety of the gene therapy platform. <\/p>\n \"The problem with stem cell therapy for ALS is that the results are generally partial and temporary,\" stated Dr. Williams. \"This is because the stem cells produce the growth factors and other proteins for a short period, but then cease. Several stem cell studies have confirmed this. Now with gene therapy, we can increase those factors by a millionfold or greater so that recuperation lasts for many years or maybe is even lifelong.\" <\/p>\n \"ALS is a complex disease with many different underlying causes,\" continued Dr. Williams. \"Our gene therapy will target several of the main underlying mechanisms related to ALS with the hopes of getting a good response in a larger group of patients. However, our platform is versatile, allowing us to change and add different target genes. We expect that soon we will be able to perform a detailed genetic analysis of the patient, identifying their exact underlying cause of ALS. Then we will be able to tailor the therapy to each individual patient.\" <\/p>\n The company has partnered with several labs for the development of its patent-pending neurotropic AAV-based gene therapy for the treatment of neurodegenerative diseases such as ALS. In fact, Neuralgene partnered with Dr. Williams' imaging and image guided treatment facility, Precision StemCell in Bogota, to begin studies using image-guided administration of gene therapy to the spinal cord. <\/p>\n \"This is a completely new therapy for ALS, and the groundwork for this technology will lead to the treatment of many other diseases,\" said Dr. Williams. Neuralgene has several other AAV gene therapies in its research and development pipeline for the treatment of neurodegenerative diseases such as Parkinson's and Multiple Sclerosis (MS). After initial testing of PRCN-829 in Colombia, Neuralgene plans to seek approval from the FDA for trials in the United States. <\/p>\n <\/p>\n See original here: <\/p>\n Gene Therapy Developed for ALS Treatment: New Biotech Company Neuralgene Enters Evaluation Phase<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" BOGOTA, Colombia, April 12, 2013 \/PRNewswire\/ -- Startup biotechnology company Neuralgene (http:\/\/neuralgene.com<\/a>) has announced that it will begin animal studies in May to evaluate the efficacy of PRCN-829, its new gene therapy agent for the treatment of amyotrophic lateral sclerosis (ALS). PRCN-829 is the first gene therapy for sporadic ALS Continue reading